Denmark: These 48 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Denmark
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Denmark: These 48 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
Tradename | Ingredient | Estimated Entry Opportunity Date |
---|---|---|
CREON | pancrelipase (amylase;lipase;protease) | 2025-08-15 |
ERIVEDGE | vismodegib | 2024-09-02 |
ESBRIET | pirfenidone | 2025-09-22 |
OLYSIO | simeprevir sodium | 2025-07-29 |
XALKORI | crizotinib | 2025-12-05 |
XTANDI | enzalutamide | 2025-05-13 |
PICATO | ingenol mebutate | 2025-12-16 |
>Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Denmark: These 48 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Denmark Patent 1,931,316
CREON is a drug marketed by There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ERIVEDGE (vismodegib) generic drug versions launch?
Generic name: vismodegib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2024
Generic Entry Controlled by: Denmark Patent 1,789,390
ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries.
See drug price trends for ERIVEDGE.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Denmark Patent 1,940,364
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Eighteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Denmark Patent 1,912,999
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Denmark Patent 2,322,516
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can XALKORI (crizotinib) generic drug versions launch?
Generic name: crizotinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2025
Generic Entry Controlled by: Denmark Patent 1,963,302
XALKORI is a drug marketed by Pf Prism Cv. There are five patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-eight countries.
See drug price trends for XALKORI.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Denmark Patent 1,893,196
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Denmark Patent 2,444,085
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: Denmark Patent 1,988,877
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-four patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Denmark Patent 1,858,864
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has forty-eight patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Denmark Patent 2,273,876
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has forty-eight patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Denmark Patent 3,494,960
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has forty-eight patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Denmark Patent 1,732,628
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Denmark Patent 1,732,629
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Denmark Patent 2,343,304
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Denmark Patent 2,987,796
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Denmark Patent 3,424,932
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-seven patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Denmark Patent 1,747,036
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: Denmark Patent 1,740,177
INCRUSE ELLIPTA is a drug marketed by
This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: Denmark Patent 2,570,128
INCRUSE ELLIPTA is a drug marketed by
This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Denmark Patent 1,747,036
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 1,819,353
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 2,030,981
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 2,260,835
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 2,261,236
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Denmark Patent 1,901,729
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Denmark Patent 2,494,969
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Denmark Patent 1,819,700
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2025
Generic Entry Controlled by: Denmark Patent 1,910,395
SPINRAZA is a drug marketed by Biogen Idec. There are eight patents protecting this drug.
This drug has one hundred and one patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2025
Generic Entry Controlled by: Denmark Patent 2,548,560
SPINRAZA is a drug marketed by Biogen Idec. There are eight patents protecting this drug.
This drug has one hundred and one patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2025
Generic Entry Controlled by: Denmark Patent 3,308,788
SPINRAZA is a drug marketed by Biogen Idec. There are eight patents protecting this drug.
This drug has one hundred and one patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can NEURACEQ (florbetaben f-18) generic drug versions launch?
Generic name: florbetaben f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 17, 2024
Generic Entry Controlled by: Denmark Patent 2,213,652
NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.
This drug has thirty-five patent family members in twenty-seven countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.
When can VARITHENA (polidocanol) generic drug versions launch?
Generic name: polidocanol
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 21, 2025
Generic Entry Controlled by: Denmark Patent 1,945,533
VARITHENA is a drug marketed by Provensis. There are four patents protecting this drug.
This drug has ninety-seven patent family members in thirty countries.
See drug price trends for VARITHENA.
The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this generic product. Additional details are available on the polidocanol profile page.
When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Denmark Patent 1,612,203
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA
See drug price trends for NUCYNTA.
The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Denmark Patent 1,799,633
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA
See drug price trends for NUCYNTA.
The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can OTREXUP (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 24, 2025
Generic Entry Controlled by: Denmark Patent 1,850,892
OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.
This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP
See drug price trends for OTREXUP.
The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 18, 2025
Generic Entry Controlled by: Denmark Patent 1,863,839
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 18, 2025
Generic Entry Controlled by: Denmark Patent 2,322,546
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Denmark Patent 2,343,304
KERYDIN is a drug marketed by Anacor Pharms Inc.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Denmark Patent 2,987,796
KERYDIN is a drug marketed by Anacor Pharms Inc.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Denmark Patent 3,424,932
KERYDIN is a drug marketed by Anacor Pharms Inc.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can NEVANAC (nepafenac) generic drug versions launch?
Generic name: nepafenac
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 02, 2024
Generic Entry Controlled by: Denmark Patent 1,819,362
NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.
This drug has twenty-seven patent family members in twenty-three countries.
See drug price trends for NEVANAC.
The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.
When can FYCOMPA (perampanel) generic drug versions launch?
Generic name: perampanel
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 06, 2024
Generic Entry Controlled by: Denmark Patent 1,764,361
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA
See drug price trends for FYCOMPA.
The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 1,753,406
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 2,298,288
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can LYRICA CR (pregabalin) generic drug versions launch?
Generic name: pregabalin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2025
Generic Entry Controlled by: Denmark Patent 1,945,186
LYRICA CR is a drug marketed by Upjohn. There are three patents protecting this drug and four Paragraph IV challenges. Nine tentatively approved generics are ready to enter the market.
This drug has thirty-seven patent family members in thirty-three countries.
See drug price trends for LYRICA CR.
The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-one suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.
When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Denmark Patent 1,612,203
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER
See drug price trends for NUCYNTA ER.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Denmark Patent 1,799,633
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER
See drug price trends for NUCYNTA ER.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can TRACLEER (bosentan) generic drug versions launch?
Generic name: bosentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 17, 2025
Generic Entry Controlled by: Denmark Patent 1,883,397
TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER
See drug price trends for TRACLEER.
The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.
When can APTIOM (eslicarbazepine acetate) generic drug versions launch?
Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Denmark Patent 1,915,346
APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM
See drug price trends for APTIOM.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.
When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?
Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2024
Generic Entry Controlled by: Denmark Patent 1,838,677
BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.
This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering BELVIQ
See drug price trends for BELVIQ.
The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 01, 2025
Generic Entry Controlled by: Denmark Patent 1,902,029
BOSULIF is a drug marketed by Pf Prism Cv. There are five patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 21, 2024
Generic Entry Controlled by: Denmark Patent 1,753,431
CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.
This drug has forty patent family members in thirty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Denmark Patent 1,695,965
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can DUEXIS (famotidine; ibuprofen) generic drug versions launch?
Generic name: famotidine; ibuprofen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 18, 2025
Generic Entry Controlled by: Denmark Patent 2,043,637
DUEXIS is a drug marketed by Horizon. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS
See drug price trends for DUEXIS.
The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Denmark Patent 1,819,700
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Denmark Patent 1,919,874
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Denmark Patent 2,251,319
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Denmark Patent 2,261,215
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 26, 2025
Generic Entry Controlled by: Denmark Patent 1,884,242
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has sixty-eight patent family members in twenty-four countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 26, 2025
Generic Entry Controlled by: Denmark Patent 2,422,783
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has sixty-eight patent family members in twenty-four countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?
Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 20, 2024
Generic Entry Controlled by: Denmark Patent 1,740,163
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA
See drug price trends for NATAZIA.
The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 07, 2025
Generic Entry Controlled by: Denmark Patent 1,868,579
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 1,753,406
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 2,298,288
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Denmark Patent 1,919,874
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Denmark Patent 2,251,319
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2025
Generic Entry Controlled by: Denmark Patent 2,261,215
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 19, 2025
Generic Entry Controlled by: Denmark Patent 1,871,347
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 20, 2024
Generic Entry Controlled by: Denmark Patent 1,636,190
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can XIFAXAN (rifaximin) generic drug versions launch?
Generic name: rifaximin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 03, 2025
Generic Entry Controlled by: Denmark Patent 1,698,630
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.
This drug has two hundred and eight patent family members in forty countries. There has been litigation on patents covering XIFAXAN
See drug price trends for XIFAXAN.
The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2024
Generic Entry Controlled by: Denmark Patent 1,746,999
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-two patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can AEMCOLO (rifamycin) generic drug versions launch?
Generic name: rifamycin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 25, 2024
Generic Entry Controlled by: Denmark Patent 1,763,339
AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries.
See drug price trends for AEMCOLO.
The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the rifamycin profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Denmark Patent 1,707,562
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 10, 2025
Generic Entry Controlled by: Denmark Patent 1,846,384
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can VYONDYS 53 (golodirsen) generic drug versions launch?
Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Denmark Patent 1,766,010
VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.
This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53
The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.
When can VYONDYS 53 (golodirsen) generic drug versions launch?
Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Denmark Patent 2,206,781
VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.
This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53
The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 22, 2025
Generic Entry Controlled by: Denmark Patent 1,879,873
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.
This drug has twenty-six patent family members in twenty countries.
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can KOSELUGO (selumetinib sulfate) generic drug versions launch?
Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2025
Generic Entry Controlled by: Denmark Patent 1,968,948
KOSELUGO is a drug marketed by Astrazeneca. There are five patents protecting this drug.
This drug has one hundred and ninety-eight patent family members in forty-four countries.
See drug price trends for KOSELUGO.
The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Denmark Patent 1,874,117
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-three patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Denmark Patent 2,465,580
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-three patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Denmark Patent 3,045,206
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-three patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Denmark Patent 3,284,520
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-three patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: